EP3645739A4 - Procédés et compositions pour le traitement du mélanome - Google Patents

Procédés et compositions pour le traitement du mélanome Download PDF

Info

Publication number
EP3645739A4
EP3645739A4 EP18823414.0A EP18823414A EP3645739A4 EP 3645739 A4 EP3645739 A4 EP 3645739A4 EP 18823414 A EP18823414 A EP 18823414A EP 3645739 A4 EP3645739 A4 EP 3645739A4
Authority
EP
European Patent Office
Prior art keywords
melanoma
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18823414.0A
Other languages
German (de)
English (en)
Other versions
EP3645739A2 (fr
Inventor
Thomas G. Graeber
Jennifer TSOI
Antoni Ribas
Lidia ROBERT
Nicolaos PALASKAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP3645739A2 publication Critical patent/EP3645739A2/fr
Publication of EP3645739A4 publication Critical patent/EP3645739A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP18823414.0A 2017-06-28 2018-06-27 Procédés et compositions pour le traitement du mélanome Pending EP3645739A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762525969P 2017-06-28 2017-06-28
US201862650051P 2018-03-29 2018-03-29
PCT/US2018/039822 WO2019006005A2 (fr) 2017-06-28 2018-06-27 Procédés et compositions pour le traitement du mélanome

Publications (2)

Publication Number Publication Date
EP3645739A2 EP3645739A2 (fr) 2020-05-06
EP3645739A4 true EP3645739A4 (fr) 2021-07-14

Family

ID=64742693

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18823414.0A Pending EP3645739A4 (fr) 2017-06-28 2018-06-27 Procédés et compositions pour le traitement du mélanome

Country Status (3)

Country Link
US (1) US12213977B2 (fr)
EP (1) EP3645739A4 (fr)
WO (1) WO2019006005A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52889A (fr) * 2018-06-15 2021-04-21 Flagship Pioneering Innovations V Inc Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
WO2020072366A1 (fr) * 2018-10-01 2020-04-09 The Regents Of The University Of California Méthodes de traitement du cancer avec des activateurs de capteur d'arn double brin et une thérapie cellulaire adoptive
RS64836B1 (sr) 2018-10-22 2023-12-29 C4X Discovery Ltd Terapijska jedinjenja
CN109988841B (zh) * 2019-04-04 2022-08-12 首都医科大学附属北京妇产医院 Kcp基因在宫颈癌紫杉醇敏感性检测中的应用
US20230114107A1 (en) * 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN114555122A (zh) * 2019-12-26 2022-05-27 中外制药株式会社 预测癌症细胞对gpx4抑制剂敏感性的方法
EP3915585A1 (fr) * 2020-05-26 2021-12-01 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Combinaisons thérapeutiques comprenant des agonistes de la ferroptose pour le traitement de troubles prolifératifs
CN112111269B (zh) * 2020-10-22 2023-09-15 中国工程物理研究院核物理与化学研究所 一种荧光和镥-177双标记生物分子及其制备方法与应用
KR102710867B1 (ko) * 2020-12-18 2024-09-27 (주)인비보텍 Oligodendrocyte transcription factor 2 억제제를 유효성분으로 포함하는 흑색종 치료 효과 증진용 약학적 조성물
KR102679204B1 (ko) * 2021-02-10 2024-06-27 한국생명공학연구원 GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물
EP4355331A4 (fr) * 2021-06-15 2025-05-07 The Regents Of The University Of California Méthodes et compositions pour traiter un mélanome
CN113980963B (zh) * 2021-09-03 2024-05-28 中山大学 一种寡核苷酸rna双链分子及其在制备治疗恶性肿瘤药物中的应用
CN113827599A (zh) * 2021-09-23 2021-12-24 天津国际生物医药联合研究院 去甲泽拉木醛在抗登革病毒感染中的潜在应用
WO2023118165A1 (fr) * 2021-12-21 2023-06-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions de traitement d'un mélanome
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
EP4479046A4 (fr) * 2022-02-15 2026-02-18 The Regents Of Univ Of California Méthodes pour empêcher une résistance thérapeutique dans un mélanome par blocage de l'instabilité génomique
CN115192600A (zh) * 2022-08-25 2022-10-18 吉林大学 靶向pbx1启动子区g-四链体的反义寡核苷酸在制备治疗黑色素瘤药物中的应用
WO2024229387A1 (fr) * 2023-05-03 2024-11-07 Ohio State Innovation Foundation Biomarqueur pour la prédiction de résultats d'immunothérapie et stratégies de traitement de précision et leurs utilisations
CN116585490B (zh) * 2023-05-15 2025-07-11 重庆大学 一种微环境响应性免疫激活水凝胶及其制备方法和应用
CN117180440A (zh) * 2023-10-26 2023-12-08 中国药科大学 Gpx4抑制剂联合parp抑制剂在制备抗肿瘤药物中的应用
WO2025219330A1 (fr) * 2024-04-15 2025-10-23 Institut National de la Santé et de la Recherche Médicale Détection de ppix pour utilisation dans des méthodes de prédiction de la sensibilité à la ferroptose du mélanome et de la résistance aux thérapies ciblées

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095078A1 (en) * 2010-10-07 2012-04-19 Sanford-Burnham Medical Research Institute Methods of diagnosis and treatment of melanoma
WO2016196201A1 (fr) * 2015-05-29 2016-12-08 Memorial Sloan Kettering Cancer Center Procédés de traitement utilisant des nanoparticules très petites pour induire la mort cellulaire de cellules cancéreuses privées de nutriments par ferroptose

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070154889A1 (en) * 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20110177042A1 (en) * 2008-10-03 2011-07-21 Meenhard Herlyn Method for Dedifferentiating Melanocytes
WO2012027716A1 (fr) * 2010-08-27 2012-03-01 Collabrx, Inc. Procédé pour traiter un mélanome chez des sujets résistants à un inhibiteur de braf
US10016402B2 (en) * 2011-02-08 2018-07-10 Children's Medical Center Corporation Methods for treatment of melanoma
US9580398B2 (en) 2012-04-02 2017-02-28 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
EP3791870A1 (fr) 2013-12-02 2021-03-17 The Trustees of Columbia University in the City of New York Modulation de la ferroptose et traitement des troubles excitotoxiques
WO2015153514A1 (fr) * 2014-03-31 2015-10-08 Genentech, Inc. Thérapie combinatoires comprenant des agents anti-angiogenèse et des agonistes se liant à ox40
WO2017019664A1 (fr) * 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions et méthodes de traitement du cancer
WO2017058007A1 (fr) * 2015-10-01 2017-04-06 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inhibiteurs de l'histone désacétylase utilisables dans le traitement d'un mélanome résistant aux médicaments
US11175296B2 (en) * 2016-10-26 2021-11-16 Washington University Methods of diagnosing and treating cancer comprising ME1
WO2018218087A1 (fr) * 2017-05-24 2018-11-29 K-Gen, Inc. Méthodes de traitement du cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120095078A1 (en) * 2010-10-07 2012-04-19 Sanford-Burnham Medical Research Institute Methods of diagnosis and treatment of melanoma
WO2016196201A1 (fr) * 2015-05-29 2016-12-08 Memorial Sloan Kettering Cancer Center Procédés de traitement utilisant des nanoparticules très petites pour induire la mort cellulaire de cellules cancéreuses privées de nutriments par ferroptose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARRETT PARKER WAGNER ET AL: "Diagnostic dilemma: late presentation of amelanotic BRAF-negative metastatic malignant melanoma resembling clear cell sarcoma - a case re", DIAGNOSTIC PATHOLOGY, BIOMED CENTRAL LTD, LO, vol. 8, no. 1, 25 November 2013 (2013-11-25), pages 192, XP021171502, ISSN: 1746-1596, DOI: 10.1186/1746-1596-8-192 *
BERROCAL ALFONSO ET AL: "Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations", ADVANCES IN THERAPY, HEALTH COMMUNICATIONS, METUCHEN, NJ, US, vol. 31, no. 9, 22 August 2014 (2014-08-22), pages 945 - 960, XP035399106, ISSN: 0741-238X, [retrieved on 20140822], DOI: 10.1007/S12325-014-0148-2 *

Also Published As

Publication number Publication date
WO2019006005A3 (fr) 2019-02-07
US12213977B2 (en) 2025-02-04
US20200163966A1 (en) 2020-05-28
EP3645739A2 (fr) 2020-05-06
WO2019006005A2 (fr) 2019-01-03

Similar Documents

Publication Publication Date Title
EP3947715A4 (fr) Procédés et compositions pour le traitement du cancer
EP3894392A4 (fr) Compositions et procédés pour le traitement du cancer
EP3555077A4 (fr) Compositions et procédés pour le traitement du cancer
MA51306A (fr) Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase
EP3377516A4 (fr) Procédés et compositions pour le traitement du cancer
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
EP3474879A4 (fr) Compositions et procédés de traitement d'un mélanome
EP3302379A4 (fr) Compositions et méthodes pour le traitement du ptérygion
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
EP3347469A4 (fr) Méthodes et compositions pour le traitement du glaucome
EP3624896A4 (fr) Compositions et procédés pour le traitement du cancer avec mutations de braf atypiques
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA47613A (fr) Compositions et procédés de traitement du cancer
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3908601A4 (fr) Procédés et compositions pour le traitement du cancer
EP3405172A4 (fr) Procédés et compositions pour le traitement du vieillissement cutané
EP3462883A4 (fr) Compositions et méthodes pour le traitement du cancer
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
IL262487B (en) Compounds and methods for treating neurological and cardiovascular conditions
EP3681498A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3347025A4 (fr) Méthodes et compositions pour le traitement du cancer
EP3429609A4 (fr) Compositions et procédés pour le traitement de déficits en collagène de type vii
EP3403099A4 (fr) Procédés et compositions pour le traitement du cancer
EP3353204A4 (fr) Méthodes et compositions pour le traitement du cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200108

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20180101AFI20210305BHEP

Ipc: A61K 33/42 20060101ALI20210305BHEP

Ipc: G01N 33/574 20060101ALI20210305BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20210615

RIC1 Information provided on ipc code assigned before grant

Ipc: C12Q 1/68 20180101AFI20210609BHEP

Ipc: A61K 33/42 20060101ALI20210609BHEP

Ipc: G01N 33/574 20060101ALI20210609BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230928